Search results
Results from the WOW.Com Content Network
Moussa B. H. Youdim (born, February 28, 1940) is a world famous Israeli neuroscientist specializing in neurochemistry and neuropharmacology. He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl and rasagiline as anti-Parkinson drugs which possess neuroprotective activities.
A small new trial published in the journal Nature Medicine describes what would be two firsts for Parkinson's disease, if they pan out: a diagnostic test and a potential immune-based treatment ...
The researchers inserted the device into two patients with Parkinson's disease who had traditional DBS but continued to experience dyskinesia after adjustment by a neurologist. Later on, they compared the results of the adaptive stimulation system with traditional stimulation set manually on two patients, and found that the adaptive approach ...
However, with this treatment, the number of substantia nigra neurons decrease so it becomes less efficient. [2] These treatments try to reduce the symptoms of the patient focusing on increasing the production of dopamine but they do not cure the disease. The new treatments for PD are in clinical trials and most of them are centered on gene therapy.
The first cell-based therapy investigated for Parkinson's disease utilized the adrenal medulla. The adrenal medulla is the innermost part of the adrenal gland and contains neural crest derived chromaffin cells which secrete norepinephrine , epinephrine and to a far lesser extent dopamine into the blood.
The study, published in the Journal of Neurology, Neurosurgery and Psychiatry, looked at two groups – one group of about 143 patients with Parkinson's disease and active tai chi training, and ...
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
In January 2021 the FDA approved the first clinical trial for an investigational stem cell therapy to restore lost brain cells in people with advanced Parkinson's disease. [ 40 ] Healthy adult brains contain neural stem cells , which divide to maintain general stem-cell numbers, or become progenitor cells .